DIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024
BROSSARD, Quebec, May 06, 2024 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB:DGNOF), a provider of healthcare services in early detection of certain critical health issues, in collaboration with ETS, École de Technologie Supérieure, is proud to announce its participation in the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting. DIAGNOS will showcase its latest advancements in artificial intelligence applied to retinal imaging, aiming to revolutionize the way retinal anomalies are detected and diagnosed.
Related news for (DGNOF)
- DIAGNOS Welcomes Former White House Economic Adviser Dr. Tomas J. Philipson to its Advisory Board for the US Market
- DIAGNOS Announces the Engagement of Allele Capital Partners
- DIAGNOS Announces Amendment to Convertible Debentures
- DIAGNOS announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System application
- DIAGNOS Provides Additional Information on Amendment to Convertible Debentures